Global Thrombophilia Market – Industry Trends and Forecast to 2030

Thrombophilia Market Analysis and Size

The different developed technologies used for thrombophilia testing and growing elderly  population globally are the primary factors that boost the market. The increase in the number of people with genetic mutations worldwide is also evaluated to drive growth to the market segment in the imminent time. Different R&D activities are leading in the expansion of the market. The market is primarily driven by high occurrence of thrombophilia and huge financial investment on R&D activities.

Data Bridge Market Research analyses a growth rate in the thrombophilia market  in the forecast period 2023-2030. The expected CAGR of thrombophilia market   tend to be around 7% in the mentioned forecast period. The market is valued at USD 15.95 billion in 2022, and it would grow upto USD 27.41 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Thrombophilia Market Scope and Segmentation

Market Definition

Thrombophilia is a hypercoagulable state, which may cause pathogenic thromboembolism because of the heredity or acquired conditions that results in a loss of balance between natural coagulant and anticoagulant protein. Some of the thrombophilia condition can cause incidence of recurrent and excessive venous thrombolism or severe arterial events. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period

Thrombophilia Market Dynamics

Drivers

• Increase in Elderly Population

The elderly population is projected to rise the patient population worldwide, that boots the global market during the forecast period. As per the records of the WHO, the global elderly population is anticipated to reach about 2 billion by 2050 from 617 million in 2015. This condition is common in this population and which boost the market growth.

• Increasing Demand for Oral Drugs

Oral drugs is anticipated to boost the market growth due to its convenient mode. The segment is anticipated to rise the global market as most of the products are accessible in capsule and tablet form and it is a very convenient route of administration.

Opportunities

• Rise in Mergers and Acquisitions

Increased mergers and acquisitions to develop and launch several advanced drugs and treatment are helping in the growth of the market. The drug launches and approvals from drug regulatory authorities are anticipated to create major growth opportunities during the forecast period 2023-2030. For instance, in December 2020, Glenmark Pharmaceuticals received a tentative approval by the U.S. FDA for Dabigatran Etexilate capsules. It will be accessible in the strengths of 75 mg, 110 mg, and 150 mg. This product is a generic version of Pradaxa capsules.

• Increasing Demand For Coagulation Tests

Numerous coagulation tests that are available now for the increased identification of thrombophilia such as bleeding time, complete blood count, Factor V assay, fibrinogen level, thrombin time,  and platelet count. These tests are widely used for thrombophilia patients. This creates more opportunity in the market.

Restraints/Challenges

• Dearth of Skilled Professionals

Lack of professionals who are not trained enough and unaware of the knowledge of the treatment methods for this disease could reduce the growth of the global thrombophilia market during the forecast period 2023-2030. These patients need to be handled well and treatment must be done quickly thus, unskilled professionals hamper the market growth.

• High Cost of Treatment

The huge expenditure of the treatment methods impede the market growth. Drugs such as heparin, warfarin and others are quiet high and thus it restrains the growth of the market.

This thrombophilia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the thrombophilia market  contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Thrombophilia Market Scope

The thrombophilia market is segmented on the basis of type, drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Factor V Leiden
• Prothrombin 20210
• Antiphospholipid Syndrome
• Others

Drugs

• Heparin
• Warfarin
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Thrombophilia Market Regional Analysis/Insights

The thrombophilia market  is analyzed and market size insights and trends are provided by type, drugs, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the thrombophilia market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the high demand for disease-specific treatment, rise in adoption of newer technologies, presence of refined healthcare expenditure, increased patient awareness level, and high prevalence of bleeding disorders.

Asia-Pacific dominates the market due to large number of generic manufacturer and rise in government initiatives and specialist communities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Thrombophilia Market Share Analysis

The thrombophilia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to thrombophilia market.

Key players operating in the thrombophilia market include:

• Pfizer Inc (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Mylan N.V. (U.S.)
• Aspen Holdings (U.S.)
• Changzhaou Qianhong Bio-pharma Co., ltd. (China)
• Fresenius Kabi AG (Germany)
• Hebei Changshan Biochemical Pharmaceutical Co. Ltd. (China)
• Hikma Pharmaceuticals PLC (Japan)
• Novartis AG (U.S)
• Shanghai Fosun Pharmaceutical (Group) Co., Ltd (China)
• Hepalink Group. (China)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Yino Pharma Limited (China)

SKU-53620